þ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
94-3076866
|
|
(State or Other Jurisdiction of Incorporation)
|
(IRS Employer Identification No.)
|
Large Accelerated Filer | o | Accelerated Filer | o |
Non-Accelerated Filer | o | Smaller reporting company | þ |
(Do not check if a smaller reporting company) |
Item 1. | Financial Statements | 3 | |||
Balance Sheets as of June 30, 2011 (unaudited) and December 31, 2010 | 3 | ||||
Statements of Operations (unaudited) for the three-month and six-month periods ended June 30, 2011 and 2010 | 4 | ||||
Statements of Cash Flows (unaudited) for the six-month periods ended June 30, 2011 and 2010 | 5 | ||||
Notes to Financial Statements (unaudited) | 6 | ||||
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 10 | |||
Item 4. | Controls and Procedures | 13 | |||
PART II. OTHER INFORMATION | |||||
Item 6. | Exhibits | 14 | |||
Signatures | 15 | ||||
Index to Exhibits | 16 |
ITEM 1.
|
FINANCIAL STATEMENTS
|
June 30,
|
December 31,
|
|||||||
2011
|
2010
|
|||||||
Assets |
|
|||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$ | 36,145 | $ | 3,211 | ||||
Accounts receivable, trade, net of allowance for doubtful accounts
|
||||||||
of $1,100 at June 30, 2011 and December 31, 2010, respectively
|
395,324 | 338,899 | ||||||
Inventories
|
509,572 | 410,486 | ||||||
Prepaid expenses and other current assets
|
66,530 | 62,377 | ||||||
Total current assets
|
1,007,571 | 814,973 | ||||||
Property and equipment
|
||||||||
Furniture and computer equipment
|
174,166 | 170,256 | ||||||
Manufacturing and other equipment
|
582,136 | 542,775 | ||||||
Subtotal
|
756,302 | 713,031 | ||||||
Less: Accumulated depreciation and amortization
|
(398,524 | ) | (352,331 | ) | ||||
Net property and equipment
|
357,778 | 360,700 | ||||||
Long term deposits
|
36,166 | 36,166 | ||||||
Deferred financing costs
|
70,466 | 97,220 | ||||||
Total assets
|
$ | 1,471,981 | $ | 1,309,059 | ||||
Liabilities and Stockholders’ Equity (Deficiency)
|
||||||||
Current liabilities
|
||||||||
Accounts payable
|
$ | 347,063 | $ | 117,068 | ||||
Accrued expenses
|
48,022 | 108,015 | ||||||
Accrued compensation
|
87,689 | 95,619 | ||||||
Deferred revenue
|
20,000 | 20,000 | ||||||
Total current liabilities
|
502,774 | 340,702 | ||||||
Long term liabilities
|
||||||||
Promissory notes payable, related parties
|
9,653,127 | 9,033,127 | ||||||
Accrued interest, related parties
|
1,680,756 | 1,354,975 | ||||||
Deferred revenue, long term
|
119,167 | 129,167 | ||||||
Total liabilities
|
11,955,824 | 10,857,971 | ||||||
Commitments and Contingencies
|
||||||||
Stockholders' equity (deficiency)
|
||||||||
Common stock, $0.001 par value; 100,000,000 shares
|
||||||||
authorized, 69,679,854 issued and outstanding at June 30, 2011 and December 31, 2010
|
69,680 | 69,680 | ||||||
Additional paid-in capital
|
42,708,130 | 42,576,260 | ||||||
Accumulated deficit
|
(53,261,653 | ) | (52,194,852 | ) | ||||
Total stockholders' equity (deficiency)
|
(10,483,843 | ) | (9,548,912 | ) | ||||
Total liabilities and stockholders' equity (deficiency)
|
$ | 1,471,981 | $ | 1,309,059 |
Three-month Period Ended
June 30,
|
Six-month Period Ended
June 30,
|
|||||||||||||||
2011
|
2010
|
2011
|
2010
|
|||||||||||||
Revenue
|
||||||||||||||||
Product sales
|
$ | 617,848 | $ | 462,771 | $ | 1,223,647 | $ | 970,680 | ||||||||
Licensing revenue
|
5,000 | 5,000 | 10,000 | 10,000 | ||||||||||||
Total revenue
|
622,848 | 467,771 | 1,233,647 | 980,680 | ||||||||||||
Cost of product sales
|
288,915 | 274,153 | 657,515 | 548,341 | ||||||||||||
Gross profit
|
333,933 | 193,618 | 576,132 | 432,339 | ||||||||||||
Operating expenses
|
||||||||||||||||
Research and development
|
133,390 | 81,502 | 292,183 | 148,435 | ||||||||||||
Sales and marketing
|
59,132 | 117,017 | 142,440 | 240,046 | ||||||||||||
General and administrative
|
401,423 | 386,626 | 855,798 | 829,200 | ||||||||||||
Total operating expenses
|
593,945 | 585,145 | 1,290,421 | 1,217,681 | ||||||||||||
Operating loss
|
(260,012 | ) | (391,527 | ) | (714,289 | ) | (785,342 | ) | ||||||||
Other income (expenses)
|
||||||||||||||||
Interest income
|
2 | 76 | 23 | 112 | ||||||||||||
Interest expense
|
(165,239 | ) | (145,693 | ) | (325,781 | ) | (282,065 | ) | ||||||||
Loss on sale of assets
|
- | - | - | (1,626 | ) | |||||||||||
Amortization of deferred financing costs
|
(11,430 | ) | - | (26,754 | ) | - | ||||||||||
Total other income (expenses)
|
(176,667 | ) | (145,617 | ) | (352,512 | ) | (283,579 | ) | ||||||||
Net Loss
|
$ | (436,679 | ) | $ | (537,144 | ) | $ | (1,066,801 | ) | $ | (1,068,921 | ) | ||||
Basic and diluted net loss per common share
|
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.02 | ) | ||||
Basic and diluted weighted average common shares used to calculate net loss per common share
|
69,679,854 | 69,679,854 | 69,679,854 | 69,679,854 |
Six-month Period Ended
June 30,
|
||||||||
2011
|
2010
|
|||||||
Cash flows from operating activities
|
||||||||
Net loss
|
$ | (1,066,801 | ) | $ | (1,068,921 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities
|
||||||||
Depreciation and amortization
|
46,193 | 27,753 | ||||||
Loss on disposal of property and equipment
|
- | 1,626 | ||||||
Share-based compensation expense
|
131,870 | 79,221 | ||||||
Amortization of deferred financing costs
|
26,754 | - | ||||||
Change in operating assets and liabilities
|
||||||||
(Increase) Decrease in
|
||||||||
Accounts receivable, trade
|
(56,425 | ) | 30,124 | |||||
Inventories
|
(99,086 | ) | (174,212 | ) | ||||
Prepaid expenses and other current assets
|
(4,153 | ) | 6,368 | |||||
Increase (Decrease) in
|
||||||||
Accounts payable
|
229,995 | 150,446 | ||||||
Accrued expenses and compensation
|
(67,923 | ) | 17,990 | |||||
Accrued interest, related parties
|
325,781 | 282,065 | ||||||
Deferred revenue
|
(10,000 | ) | (10,000 | ) | ||||
Net cash used in operating activities
|
(543,795 | ) | (657,540 | ) | ||||
Cash flows from investing activity
|
||||||||
Purchase of property and equipment
|
(43,271 | ) | (13,730 | ) | ||||
Net cash used in investing activity
|
(43,271 | ) | (13,730 | ) | ||||
Cash flows from financing activity
|
||||||||
Proceeds from promissory notes payable, related parties
|
620,000 | 600,000 | ||||||
Net cash provided by financing activity
|
620,000 | 600,000 | ||||||
Net increase (decrease) in cash and cash equivalents
|
32,934 | (71,270 | ) | |||||
Cash and cash equivalents - beginning of period
|
3,211 | 139,151 | ||||||
Cash and cash equivalents - end of period
|
$ | 36,145 | $ | 67,881 |
1.
|
Nature of the Business
|
2.
|
Financial Condition and Going Concern
|
3.
|
Summary of Significant Accounting Policies
|
4.
|
Inventory
|
June 30,
2011
|
December 31,
2010
|
|||||||
Product, Finished Goods
|
$ | 263,245 | $ | 143,338 | ||||
Product, Work in Progress
|
73,817 | 45,277 | ||||||
Raw Materials
|
172,510 | 221,871 | ||||||
Total Inventory
|
$ | 509,572 | $ | 410,486 |
5.
|
Share-based Compensation
|
Three Month Period Ended
|
Six Month Period Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2011
|
2010
|
2011
|
2010
|
|||||||||||||
Risk free interest rate
|
-
|
2.26%
|
2.25%
|
2.22%
|
||||||||||||
Dividend yield
|
-
|
0.0%
|
0.0%
|
0.0%
|
||||||||||||
Expected term (in years)
|
-
|
7
|
6.0
|
6.8
|
||||||||||||
Volatility
|
-
|
89.18%
|
93.0%
|
87.76%
|
Wgtd. Avg.
|
||||||||
Exercise
|
||||||||
Shares
|
Price
|
|||||||
Outstanding at December 31, 2010
|
14,564,815 | $ | 0.09 | |||||
Granted
|
5,570,873 | 0.08 | ||||||
Exercised
|
- | - | ||||||
Forfeited/expired
|
(2,852,579 | ) | 0.08 | |||||
Outstanding at June 30, 2011
|
17,283,109 | $ | 0.09 | |||||
Outstanding options vested and exercisable at June 30, 2011
|
9,971,841 | $ | 0.09 |
Three Month Period Ended
|
Six Month Period Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2011
|
2010
|
2011
|
2010
|
|||||||||||||
Research and development costs
|
$
|
7,693
|
$
|
-
|
$
|
18,126
|
$
|
-
|
||||||||
Sales and marketing costs
|
663
|
-
|
1,525
|
-
|
||||||||||||
General and administrative costs
|
42,406
|
42,614
|
103,099
|
79,221
|
||||||||||||
Cost of goods sold
|
2,480
|
-
|
9,120
|
-
|
||||||||||||
Total
|
$
|
53,242
|
$
|
42,614
|
$
|
131,870
|
$
|
79,221
|
6.
|
Warrants
|
7.
|
Net Loss per Common Share
|
Period Ended June 30,
|
||||||||
2011
|
2010
|
|||||||
Basic and diluted weighted average common stock shares outstanding
|
69,679,854 | 69,679,854 | ||||||
Potentially dilutive securities excluded from loss per share computations:
|
||||||||
Common stock options
|
17,283,109 | 14,589,815 | ||||||
Common stock purchase warrants
|
4,218,750 | 2,218,750 |
8.
|
Related Party Transactions
|
9.
|
Subsequent Event
|
10.
|
Contingencies
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
·
|
Recorded record revenue for the fourth sequential quarter
|
·
|
Continued penetration into our strategic market segments of biobanking, drug discovery, and regenerative medicine
|
·
|
Significant improvement in gross margin to 54%, driven by improved utilization of manufacturing capacity
|
·
|
Indirect distribution channel revenue at 25% more than the full year of 2010
|
·
|
Contract manufacturing revenue increased 40% from the second quarter of 2010
|
·
|
Continued to fulfill significant contract manufacturing orders for our strategic partners in the blood collection, transportation, and storage sub-segments of the biobanking market
|
Three Month Period Ended
|
||||||||||||||||
June 30,
|
||||||||||||||||
2011
|
2010
|
Change
|
% Change
|
|||||||||||||
Revenue
|
||||||||||||||||
Product sales
|
$
|
617,848
|
$
|
462,771
|
$
|
155,077
|
34%
|
|||||||||
Licensing revenue
|
5,000
|
5,000
|
-
|
-
|
||||||||||||
Total revenue
|
622,848
|
467,771
|
155,077
|
33%
|
||||||||||||
Cost of sales
|
288,915
|
274,153
|
14,762
|
5%
|
||||||||||||
Gross profit
|
$
|
333,933
|
$
|
193,618
|
$
|
140,315
|
72%
|
|||||||||
Gross margin %
|
54%
|
41%
|
Six Month Period Ended
|
||||||||||||||||
June 30,
|
||||||||||||||||
2011
|
2010
|
Change
|
% Change
|
|||||||||||||
Revenue
|
||||||||||||||||
Product sales
|
$
|
1,223,647
|
$
|
970,680
|
$
|
252,967
|
26%
|
|||||||||
Licensing revenue
|
10,000
|
10,000
|
-
|
-
|
||||||||||||
Total revenue
|
1,233,647
|
980,680
|
252,967
|
26%
|
||||||||||||
Cost of sales
|
657,515
|
548,341
|
109,174
|
20%
|
||||||||||||
Gross profit
|
$
|
576,132
|
$
|
432,339
|
$
|
143,793
|
33%
|
|||||||||
Gross margin %
|
47%
|
44%
|
Three Month Period Ended
|
Six Month Period Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2011
|
2010
|
2011
|
2010
|
|||||||||||||
Research and development
|
$
|
133,390
|
$
|
81,502
|
$
|
292,183
|
$
|
148,435
|
||||||||
% of revenue
|
22%
|
18%
|
24%
|
15%
|
||||||||||||
Sales and marketing
|
$
|
59,132
|
$
|
117,017
|
$
|
142,440
|
$
|
240,406
|
||||||||
% of revenue
|
10%
|
25%
|
12%
|
25%
|
||||||||||||
General and administrative
|
$
|
401,423
|
$
|
386,626
|
$
|
855,798
|
$
|
829,200
|
||||||||
% of revenue
|
65%
|
83%
|
69%
|
91%
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
BIOLIFE SOLUTIONS, INC.
|
|||
Dated: August 12, 2011
|
By:
|
/s/ Michael Rice | |
Michael Rice
|
|||
President and Chief Executive Officer
|
|||
(Principal Executive and Financial Officer) |
Exhibit No. | Description | |
31.1* | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
32.1* | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
*Filed herewith |
Dated: August 12, 2011
|
By:
|
/s/ Michael Rice | |
Michael Rice
|
|||
Chief Executive Officer and
Chief Financial Officer
|
|||
Dated: August 12, 2011
|
By:
|
/s/ Michael Rice | |
Michael Rice
|
|||
Chief Executive Officer and
Chief Financial Officer
|
|||
GM[4`=Q2%U!P6'YTM
Balance Sheets (Parenthetical) (USD $)
|
Jun. 30, 2011
|
Dec. 31, 2010
|
---|---|---|
Accounts receivable allowances | $ 1,100 | $ 1,100 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, authorized | 100,000,000 | 100,000,000 |
Common stock, issued | 69,679,854 | 69,679,854 |
Statements of Operations (Unaudited) (USD $)
|
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2011
|
Jun. 30, 2010
|
Jun. 30, 2011
|
Jun. 30, 2010
|
|
Revenue | Â | Â | Â | Â |
Product sales | $ 617,848 | $ 462,771 | $ 1,223,647 | $ 970,680 |
Licensing revenue | 5,000 | 5,000 | 10,000 | 10,000 |
Total revenue | 622,848 | 467,771 | 1,233,647 | 980,680 |
Cost of product sales | 288,915 | 274,153 | 657,515 | 548,341 |
Gross profit | 333,933 | 193,618 | 576,132 | 432,339 |
Operating expenses | Â | Â | Â | Â |
Research and development | 133,390 | 81,502 | 292,183 | 148,435 |
Sales and marketing | 59,132 | 117,017 | 142,440 | 240,046 |
General and administrative | 401,423 | 386,626 | 855,798 | 829,200 |
Total  operating expenses | 593,945 | 585,145 | 1,290,421 | 1,217,681 |
Operating loss | (260,012) | (391,527) | (714,289) | (785,342) |
Other income (expenses) | Â | Â | Â | Â |
Interest income | 2 | 76 | 23 | 112 |
Interest expense | (165,239) | (145,693) | (325,781) | (282,065) |
Loss on disposal of property and equipment | 0 | 0 | 0 | (1,626) |
Amortization of deferred financing costs | (11,430) | 0 | (26,754) | 0 |
Total other income (expenses) | (176,667) | (145,617) | (352,512) | (283,579) |
Net Loss | $ (436,679) | $ (537,144) | $ (1,066,801) | $ (1,068,921) |
net loss per common share Basic | (0.01) | (0.01) | (0.02) | (0.02) |
net loss per common share Diluted | (0.01) | (0.01) | (0.02) | (0.02) |
Weighted average common shares used to calculate net loss per common share Basic | 69,679,854 | 69,679,854 | 69,679,854 | 69,679,854 |
Weighted average common shares used to calculate net loss per common share Diluted | 69,679,854 | 69,679,854 | 69,679,854 | 69,679,854 |
Document and Entity Information
|
6 Months Ended | |
---|---|---|
Jun. 30, 2011
|
Aug. 12, 2011
|
|
Entity Registrant Name | BIOLIFE SOLUTIONS INC | Â |
Entity Central Index Key | 0000834365 | Â |
Document Type | 10-Q | Â |
Document Period End Date | Jun. 30, 2011 | |
Amendment Flag | false | Â |
Current Fiscal Year End Date | --12-31 | Â |
Is Entity a Well-known Seasoned Issuer? | No | Â |
Is Entity a Voluntary Filer? | No | Â |
Is Entity's Reporting Status Current? | Yes | Â |
Entity Filer Category | Smaller Reporting Company | Â |
Entity Common Stock, Shares Outstanding | Â | 69,679,854 |
Document Fiscal Period Focus | Q2 | Â |
Document Fiscal Year Focus | 2011 | Â |
"+ text.join( "
\n" ) +"
" + text[p] + "
\n"; } } }else{ formatted = '' + raw + '
'; } html = ''+ "\n"+''+ "\n"+''+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+' | '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
Net Loss per Common Share
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Net Loss per Common Share |
Basic net loss per common share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding during the period. Common stock equivalents are excluded for the periods ended June 30, 2011 and 2010, since the effect is anti-dilutive due to the Companys net losses. Common stock equivalents include stock options and warrants. Basic weighted average common shares outstanding, and the potentially dilutive securities excluded from loss per share computations because they are anti-dilutive, are as follows for the periods ended June 30, 2011 and 2010, respectively:
|
Summary of Significant Accounting Policies
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Summary of Significant Accounting Policies |
Basis of Presentation
We have prepared the accompanying unaudited Financial Statements pursuant to the rules and regulations of the Securities and Exchange Commission (the SEC). Pursuant to these rules and regulations, we have condensed or omitted certain information and footnote disclosures we normally include in our annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). In managements opinion, we have made all adjustments (consisting only of normal, recurring adjustments) necessary to fairly present our financial position, results of operations and cash flows. Our interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full year. These financial statements and accompanying notes should be read in conjunction with the financial statements and notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2010 on file with the SEC.
There have been no material changes to our significant accounting policies as compared to the significant accounting policies described in the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2010.
Fair value of financial instruments
We generally have the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and notes payable. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value based on the short-term nature of these financial instruments. The carrying values of notes payable approximate their fair value because interest rates of notes payable approximate market interest rates.
Recent Accounting Pronouncements
There have been no new accounting pronouncements during the six-months ended June 30, 2011, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the year ended December 31, 2010, that are of significance, or potential significance, to us. |
Subsequent Events
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Subsequent Events |
Subsequent to June 30, 2011, we received an additional $250,000 in total from Messrs. Girschweiler and Villiger pursuant to the Facility Agreements. In August 2011, each of the Facility Agreements was amended to increase the amount available to borrow thereunder by $500,000. In connection with this amendment, the Company issued warrants to purchase 1,000,000 shares of the Companys common stock, at $0.08 per share, to each of Messrs. Girschweiler and Villiger. |
Contingencies
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Contingencies |
Legal Proceedings
The Company is a party in seven legal matters filed in the state of New York by the Company or John G. Baust, the Companys former Chief Executive Officer, and members of his extended family, that are described more fully in the Companys Annual Report on Form 10-K for the year ended December 31, 2010. During the six months ended June 30, 2011, there were no significant developments related to these complaints. The Company has not made any accrual related to future litigation outcomes as of June 30, 2011 and December 31, 2010. |
Related Party Transactions
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Related Party Transactions |
We incurred legal fees for services provided by a law firm in which a director and stockholder of the Company is a partner totaling $6,903 and $18,885 for the three and six months ended June 30, 2011, respectively, and $3,929 and $16,685 for the three and six months ended June 30, 2010, respectively. Pursuant to a consulting agreement for services provided by a director and stockholder of the Company, we incurred $24,000 and $48,000 in consulting fees during the three and six months ended June 30, 2011, respectively, and $24,000 and $48,000 during the three and six months ended June 30, 2010, respectively.
Included in accounts payable are $10,903 and $149 due to related parties for services rendered as of June 30, 2011 and December 31, 2010, respectively. |
Nature of the Business
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Nature of the Business | BioLife Solutions, Inc. ("BioLife, us, we, our, or the Company) develops and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs, and provides contracted research and development and consulting services related to the optimization of biopreservation processes and protocols. Our proprietary HypoThermosol®, CryoStor®, and generic BloodStor® biopreservation media products are marketed to cell therapy companies, pharmaceutical companies, cord blood banks, hair transplant surgeons, and suppliers of cells to the toxicology testing and diagnostic markets. All of our products are serum-free and protein-free, fully defined, and are manufactured under current Good Manufacturing Practices using United States Pharmacopeia (USP) or the highest available grade components. |
Inventory
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory |
|
Share-based Compensation
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Compensation |
The fair value of share-based payments made to employees and non-employee directors was estimated on the measurement date using the Black-Scholes model using the following weighted average assumptions:
Management applies an estimated forfeiture rate that is derived from historical employee termination data. The estimated forfeiture rate applied for the three months ended June 30, 2011 and 2010 was 9.37% and 7.45%, respectively.
A summary of the Companys stock option activity and related information for the six-months ended June 30, 2011 is as follows:
During the six-months ended June 30, 2011, options to purchase an aggregate of 750,000 shares were awarded to five outside directors which vest 100% on the first anniversary date of the awards. During the six-months ended June 30, 2011, options to purchase 2,172,934 shares were awarded to employees, which vest as follows: twenty-five percent on the first anniversary date of the award, and then one-thirty sixth of the remaining balance in each of the ensuing thirty-six months following the first anniversary date of the award. During the six-months ended June 30, 2011, options to purchase 400,000 shares were awarded to the CEO, which vested 100% upon grant of the awards, and options to purchase 2,247,939 shares were awarded to the CEO, which vest at the end of the quarter the Company achieves certain milestones.
We recorded stock compensation expense of $53,242 and $42,614 for the three months ended June 30, 2011 and 2010, respectively, and $131,870 and $79,221 for the six months ended June 30, 2011 and 2010, respectively, as follows:
As of June 30, 2011, we had approximately $465,340 of unrecognized compensation expense related to unvested stock options. We expect to recognize this compensation expense over a weighted average period of approximately 2.25 years.
There were no options granted during the quarter ended June 30, 2011. The weighted average grant-date fair value of option awards granted was $0.07 per share during the three months ended June 30, 2010. The weighted average grant-date fair value of option awards granted was $0.06 and $0.08 per share during the six-months ended June 30, 2011 and 2010, respectively.
As of June 30, 2011, there was $36,500 of aggregate intrinsic value of outstanding stock options, including $28,000 of aggregate intrinsic value of exercisable stock options. Intrinsic value is the total pretax intrinsic value for all in-the-money options (i.e., the difference between the Companys closing stock price on the last trading day of June 2011 and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options as of June 30, 2011. This amount may change, based on the fair market value of the Companys stock. |
Warrants
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Warrants |
At June 30, 2011, the Company had 4,218,750 warrants outstanding and exercisable with a weighted average exercise price of $0.10. There were no warrants issued, exercised or forfeited in the six-months ended June 30, 2011. The outstanding warrants have expiration dates between May 2012 and November 2015. During the three and six months ended June 30, 2011, the Company recorded $11,430 and $26,754, respectively, in amortization of deferred financing costs related to warrants granted in 2010 in conjunction with the restructuring of outstanding notes. The warrants were valued using the Black-Scholes option pricing model resulting in a total value of $97,220 which was recorded as Deferred financing costs in 2010 and is being amortized to expense over the term of the notes. |
Financial Condition and Going Concern
|
6 Months Ended |
---|---|
Jun. 30, 2011
|
|
Financial Condition and Going Concern |
We have been unable to generate sufficient income from operations in order to meet our operating needs and have an accumulated deficit of approximately $53 million at June 30, 2011. This raises substantial doubt about our ability to continue as a going concern.
At June 30, 2011, we had cash and cash equivalents of $36,145, compared to cash and cash equivalents of $3,211 at December 31, 2010. At June 30, 2011, we had working capital of $504,797, compared to working capital of $474,271 at December 31, 2010.
During the six-months ended June 30, 2011, net cash used in operating activities was $543,795 as compared to net cash used by operating activities of $657,540 for the six-months ended June 30, 2010. Cash used in operating activities relates primarily to funding net losses offset by changes in operating assets and liabilities and non-cash expenses related to stock options and depreciation.
Net cash used in investing activities totaled $43,271 during the six-months ended June 30, 2011, and $13,730 during the six-months ended June 30, 2010. Cash used in investing activities is due to purchase of property and equipment.
Net cash provided by financing activities totaled $620,000 for the six-months ended June 30, 2011, and $600,000 for the six-months ended June 30, 2010. Cash provided by financing activities is the result of additional funding from the Secured Multi-Draw Term Loan Facility Agreements (the Facility Agreements) with two shareholders, Thomas Girschweiler, a director and stockholder of the Company, and Walter Villiger, an affiliate of the Company.
We believe that continued access to the Facility Agreements, in combination with cash generated from customer collections, will provide sufficient funds through December 31, 2011. However, we would require additional capital in the immediate short term if our ability to draw on the Facility Agreements is restricted or terminated. Other factors that would negatively impact our ability to finance our operations include (a) significant reductions in revenue from our internal projections, (b) increased capital expenditures, (c) significant increases in cost of goods and operating expenses, or (d) an adverse outcome resulting from current litigation. We expect that we may need additional capital to reach a sustainable level of positive cash flow. Although the investors who have provided the Facility Agreements historically have demonstrated a willingness to grant access to the Facility Agreements and renegotiate terms of previous credit arrangements there is no assurance they will continue to do so in the future. If the investors were to become unwilling to provide access to additional funds through the Facility Agreements, we would need to find immediate additional sources of capital. There can be no assurance that such capital would be available at all, or, if available, that the terms of such financing would not be dilutive to stockholders. If we are unable to secure additional capital as circumstances require, we may not be able to continue our operations.
These financial statements assume that we will continue as a going concern. If we are unable to continue as a going concern, we may be unable to realize our assets and discharge our liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts nor to amounts and classification of liabilities that may be necessary should we be unable to continue as a going concern. |